Lynsey is the Head of Partnerships at Rarebase, which is a public benefit biotech company on a mission to discover and develop more treatments for rare diseases in direct partnership with people and families affected by rare disease. Prior to Rarebase, she led the World Economic Forum’s (WEF) inaugural precision medicine platform. At the WEF, she focused on spurring global collaboration between the private and public sectors and developing new governance and policy models to accelerate a precision medicine approach to healthcare. She is the former Founder and CEO of a patient advocacy non-profit that worked to increase patient engagement across hospitals for children living with rare diseases. She also worked on health policy in the California Governor’s Office and in the United Kingdom’s Parliament, House of Commons. Lynsey holds a BA from Claremont McKenna College; MSc from the London School of Economics and Political Science. Lynsey is a spokesperson and life-long patient advocate for Shriners Hospitals for Children.
Quote on joining “Similar to others living with a rare disease, I can say that genomics has given me fresh hope to continue to battle an unknown, painful disease that adversely impacts my body every day. I am supportive of Congenica’s mission because they are leading the charge to move the long-awaited possibility of genomic medicine into practice. We’ve hoped for this moment as a patient community, and the time is now to accelerate genomic applications that can provide answers about rare diseases in diagnosis, treatment and beyond.”